$Neurogene (NGNE.US)$
Neurogene's $312M War Chest Fuels Promising Rett Syndrome Treatment Progress

$Neurogene (NGNE.US)$  23 EOD?

$Neurogene (NGNE.US)$ never seen a chart like todays

$NGNE 241220 22.50C$ do you notice after trading in the 70+ range for over a year and having an insider sell off.  theres some minor bad news but undercover probablymuch  worse causing major players to remove there position. Then! you see this a buy offer for fail value price.
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money

$Kazia Therapeutics (KZIA.US)$ $Disc Medicine (IRON.US)$ $Air Transport Services (ATSG.US)$ $Globalstar (GSAT.US)$ $Tenaya Therapeutics (TNYA.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Hanryu Holdings (HRYU.US)$ $Vast Renewables (VSTE.US)$ $Neurogene (NGNE.US)$ $Advent Technologies (ADN.US)$ $Staffing 360 Solutions (STAF.US)$ $Nuwellis (NUWE.US)$ $Simpple (SPPL.US)$
📊⚡️📊

$Neurogene (NGNE.US)$ this shud b 50 or less I'm shorting

$Neurogene (NGNE.US)$
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...